showed a trendP = 0.0595
After adjusting the covariates, age, sex, and comorbidities in the multivariate analysis, the duration of treatment was a significant factor that increased the risk of developing renal events (> 1 to ≤ 3 years, risk ratio [RR] 1.2, 95% CI 1.12–1.54; P = 0.0007; > 3 to ≤ 5 years, RR: 1.38, 95% CI 1.04–1.84; P = 0.0254) while consistency of use was not statistically significant but showed a trend towards increasing the risk of developing renal events (RR: 1.24, 95% CI 0.99–1.55; P = 0.0595) (Table 3 ).